HOP Côte de Nacre

Caen 14033

0 studies enrolling now · 10 studies all time

What they study most

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Diabetes Mellitus, Type 1, Heart Failure, Leukemia, Myeloid, Acute, Lung Diseases, Interstitial, Mesothelioma, Secondary Prevention, Stroke

Studies at this site

• A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Volasertib in Combination With Low-dose Cytarabine in Patients Aged 65 Years and Above With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy (POLO-AML-2) — Completed
• EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction (EMPEROR-Reduced) — Completed
• Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung — Completed
• Efficacy and Safety of Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) — Completed
• Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS) — Completed
• Nintedanib (BIBF 1120) in Mesothelioma — Stopped early
• LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy — Completed
• Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2) — Completed
• BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation — Completed